Home

Thomas O Daniel

CIK 1538894 · see remarks · last filed 2026-06-05

Thomas O Daniel is a corporate insider who has filed 59 SEC Form 4 insider transactions across 6 companies since 2012. The most recent filing, for GOSS, was dated Jun 5, 2026. Across all open-market trades the lifetime net is −$31.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.7K across reported positions. 36 SEC filings were submitted jointly with CELGENE CORP /DE/.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$6.7K

Companies

6

Total Filings

59

Lifetime Open-Market Net

-$31.31M

Filer Profile

Reported Address
GOSSAMER BIO, INC.
3115 MERRYFIELD ROW, SUITE 120
SAN DIEGO, CA 92121
Related Filers
CELGENE CORP /DE/ — 36 joint filings, latest 2016-02-02
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GOSS Director 38,095 $0.18 $6.7K $0 9 2026-06-05
Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Director 6,370 $11.19 $71.3K $0 5 2022-06-30
LRMR Director — $3.83 — $0 2 2021-05-17
Larimar Therapeutics, Inc. (ZFGN) Delisted Director 1,621 — — $0 8 2019-06-27
Juno Therapeutics, Inc. (JUNO) Delisted Director — — — $0 2 2018-03-07
CELGENE CORP /DE/ (CELGZ) Delisted see remarks 68,965 — — -$31.31M 33 2015-12-18

Recent Filings

59 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-05 GOSS Grant (A) — $0 EDGAR
2025-06-26 GOSS Grant (A) — $0 EDGAR
2024-06-06 GOSS Grant (A) — $0 EDGAR
2023-06-09 GOSS Grant (A) — $0 EDGAR
2022-07-15 GOSS Grant (A) — $0 EDGAR
2022-06-30 Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Grant (A) — $0 EDGAR
2021-06-10 GOSS Grant (A) — $0 EDGAR
2021-06-03 Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Grant (A) — $0 EDGAR
2021-05-17 LRMR Grant (A) — $0 EDGAR
2020-09-30 LRMR Grant (A) — $0 EDGAR
Showing 1–10 of 59
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.